US-based biotechnology companies Exelixis and MSD have partnered to assess the potential of combining their respective cancer ...
Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development ...
Exelixis, an Alameda, Calif., oncology company, and Rahway, N.J., drugmaker Merck said they also plan a Phase 1/2 trial and two Phase 3 studies of zanzalintinib in combination with Merck's Welireg in ...
Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stephen Willey ...
Zacks.com on MSN9d
Exelixis Gains 20.7% in Three Months: Is This the Right Time to Buy?Shares of Exelixis, Inc. EXEL have risen 20.7% in the past three months compared with the industry’s growth of 6.3%. The ...
Alameda, California Tuesday, October 15, 2024, 14:00 Hrs [IST] ...
EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively.
Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in ...
The company is running phase 3 studies for a new product, zanzalintinib, including in treating colorectal cancer -- the second-leading cause of cancer death in the world. That's even though ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback